AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39169827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 80
Study 39169834 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care and Tai Chi training
Number of subjects: 0
Study 39170110 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg esketamine + PCEA
Number of subjects: 118
Study 39170110 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg esketamine + PCIA
Number of subjects: 118
Study 39170110 — intervention group
Group type: COMPARATOR
Intervention: saline + PCEA
Number of subjects: 118
Study 39170110 — intervention group
Group type: COMPARATOR
Intervention: saline + PCIA
Number of subjects: 118
Study 39170271 — intervention group
Group type: EXPERIMENTAL
Intervention: HAr® 0.1 % (Ribohyal®)
Number of subjects: 16
Study 39170271 — intervention group
Group type: COMPARATOR
Intervention: HA 0.1 % eye drops
Number of subjects: 16
Study 39170685 — intervention group
Group type: EXPERIMENTAL
Intervention: iVES-bPFMT (20-min iVES and 20-min bPFMT sessions, twice per week, for 3 months)
Number of subjects: 21
Study 39170685 — intervention group
Group type: COMPARATOR
Intervention: TOT implantation (trans-obturator tape surgery)
Number of subjects: 21
Study 39170956 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel intervention
Number of subjects: 61
Study 39171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nonpharmacological interventions including a daily dose of both investigational products and dietary counseling on increasing dietary fiber.
Number of subjects: 100
Study 39171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose of both investigational drugs only.
Number of subjects: 100
Study 39171074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil investigational product and placebo.
Number of subjects: 100
Study 39171074 — intervention group
Group type: COMPARATOR
Intervention: Control arm with no intervention.
Number of subjects: 100
Study 39171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer patients in 2012
Number of subjects: 119785
Study 39171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer patients in 2020
Number of subjects: 119785
Study 39171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer patients diagnosed in 2012
Number of subjects: 119785
Study 39171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer patients diagnosed in 2020
Number of subjects: 119785
Study 39171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung adenocarcinoma cases in 2012
Number of subjects: 119785
Study 39171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung adenocarcinoma cases in 2020
Number of subjects: 119785
Study 39171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung squamous cell carcinoma cases in 2012
Number of subjects: 119785
Study 39171125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung squamous cell carcinoma cases in 2020
Number of subjects: 119785
Study 39171394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide
Number of subjects: 519
Study 39171394 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 519
Study 39171394 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 519
Study 39171394 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypochloremia
Number of subjects: 519
Study 39171416 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 280
Study 39171416 — intervention group
Group type: EXPERIMENTAL
Intervention: Valera Health smartphone application
Number of subjects: 280
Study 39171416 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT + Valera Health smartphone application
Number of subjects: 280
Study 39171416 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 280
Study 39171616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fixation (circular fixation combined with insertion of percutaneous screws)
Number of subjects: 948
Study 39171616 — intervention group
Group type: COMPARATOR
Intervention: Single-plating ORIF
Number of subjects: 948
Study 39171616 — intervention group
Group type: COMPARATOR
Intervention: Bone substitute
Number of subjects: 948
Study 39171624 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone therapy for two months
Number of subjects: 4670
Study 39171624 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged prednisone therapy beyond two to three months
Number of subjects: 4670
Study 39171624 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily prednisone therapy at the onset of infection
Number of subjects: 4670
Study 39171624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower induction doses or shorter durations of prednisone therapy
Number of subjects: 4670
Study 39171639 — intervention group
Group type: COMPARATOR
Intervention: Education programmes compared to routine care alone
Number of subjects: 840
Study 39171639 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programmes for people receiving dialysis who have diabetes
Number of subjects: 840
Study 39171639 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programmes for people with diabetes and moderately increased albuminuria (A2)
Number of subjects: 840
Study 39171639 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme
Number of subjects: 840
Study 39171639 — intervention group
Group type: COMPARATOR
Intervention: Education programme plus multidisciplinary, co-ordinated care compared to routine care
Number of subjects: 840
Study 39171864 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 959
Number of subjects: 42
Study 39171864 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab RP
Number of subjects: 42
Study 39171906 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional GCs (cortisone acetate or hydrocortisone)
Number of subjects: 86
Study 39171906 — intervention group
Group type: COMPARATOR
Intervention: DR-HC
Number of subjects: 86
Study 39172032 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral spinal cord stimulation (SCS) via transcutaneous stimulation or epidural stimulation
Number of subjects: 6
Study 39172032 — intervention group
Group type: EXPERIMENTAL
Intervention: User Experience Questionnaire (UEQ)
Number of subjects: 6
Study 39172240 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible visitation (12 hours/day)
Number of subjects: 519
Study 39172240 — intervention group
Group type: COMPARATOR
Intervention: Restrictive visitation (median 1.5 hours/day)
Number of subjects: 519
Study 39172246 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 64
Study 39172363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind wandering
Number of subjects: 0
Study 39172363 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39172356 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID+ Black participants
Number of subjects: 4113
Study 39172356 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID+ females
Number of subjects: 4113
Study 39172356 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgender/non-binary/other gender participants
Number of subjects: 4113
Study 39172402 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOW program implementation
Number of subjects: 0
Study 39172402 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful sites
Number of subjects: 0
Study 39172402 — intervention group
Group type: EXPERIMENTAL
Intervention: Struggling sites
Number of subjects: 0
Study 39172428 — intervention group
Group type: EXPERIMENTAL
Intervention: $333/month unconditional cash transfer
Number of subjects: 1000
Study 39172428 — intervention group
Group type: COMPARATOR
Intervention: $20/month unconditional cash transfer
Number of subjects: 1000
Study 39172446 — intervention group
Group type: EXPERIMENTAL
Intervention: Elinzanetant 120 mg once daily for 26 weeks
Number of subjects: 399
Study 39172446 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by elinzanetant 120 mg for 14 weeks
Number of subjects: 399
Study 39172463 — intervention group
Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 375
Study 39172463 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 375
Study 39172479 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib, 300 mg by mouth twice daily until PSA doubling, clinical or radiographic progression, or unacceptable toxic effects.
Number of subjects: 51
Study 39172479 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 51
Study 39172534 — intervention group
Group type: EXPERIMENTAL
Intervention: MORE-VR (Mindfulness-Oriented Recovery Enhancement)
Number of subjects: 23
Study 39172627 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir + SoC (oseltamivir)
Number of subjects: 0
Study 39172627 — intervention group
Group type: COMPARATOR
Intervention: Placebo + SoC (oseltamivir)
Number of subjects: 0
Study 39172632 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota, live-jslm (REBYOTA®)
Number of subjects: 0
Study 39172632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39172711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 2160
Study 39172711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery with remission of type 2 diabetes (T2D)
Number of subjects: 2160
Study 39172725 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy
Number of subjects: 252
Study 39172725 — intervention group
Group type: COMPARATOR
Intervention: Open pancreatoduodenectomy
Number of subjects: 252
Study 39172730 — intervention group
Group type: EXPERIMENTAL
Intervention: ARX517 (a site-specific stable PSMA-targeted antibody-drug conjugate)
Number of subjects: 0
Study 39172730 — intervention group
Group type: EXPERIMENTAL
Intervention: ARX517
Number of subjects: 0
Study 39172743 — intervention group
Group type: EXPERIMENTAL
Intervention: D-positive RHD genotyped units transfused
Number of subjects: 5
Study 39172743 — intervention group
Group type: EXPERIMENTAL
Intervention: D-positive transfusions
Number of subjects: 5
Study 39172743 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected anti-C and anti-E
Number of subjects: 5
Study 39172760 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg weekly
Number of subjects: 40
Study 39172815 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39173075 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine (two doses administered 3 months apart)
Number of subjects: 0
Study 39173075 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine (baseline vaccination scenario)
Number of subjects: 0
Study 39173075 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine (extreme high scenario)
Number of subjects: 0
Study 39173088 — intervention group
Group type: COMPARATOR
Intervention: CEE-alone (0.625 mg daily)
Number of subjects: 26747
Study 39173088 — intervention group
Group type: COMPARATOR
Intervention: CEE plus MPA (0.625 mg CEE plus 2.5 mg MPA daily)
Number of subjects: 26747
Study 39173098 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab plus chemotherapy
Number of subjects: 492
Study 39173098 — intervention group
Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 492
Study 39173142 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback intervention
Number of subjects: 800
Study 39173142 — intervention group
Group type: COMPARATOR
Intervention: Control condition with resources for seeking care
Number of subjects: 800
Study 39173175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor treatment
Number of subjects: 0
Study 39173175 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39173182 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperandrogenic PCOS
Number of subjects: 1376
Study 39173182 — intervention group
Group type: COMPARATOR
Intervention: Nonhyperandrogenic PCOS
Number of subjects: 1376
Study 39173229 — intervention group
Group type: EXPERIMENTAL
Intervention: Plinabulin (30 mg/m²), nivolumab (1 mg/kg), ipilimumab (3 mg/kg)
Number of subjects: 39
Study 39173549 — intervention group
Group type: EXPERIMENTAL
Intervention: Allied primary healthcare intervention over 12 months
Number of subjects: 1451
Study 39173549 — intervention group
Group type: EXPERIMENTAL
Intervention: Allied primary healthcare intervention between 6 and 12 months
Number of subjects: 1451
Study 39173549 — intervention group
Group type: EXPERIMENTAL
Intervention: Total allied healthcare costs
Number of subjects: 1451
Study 39173550 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Adaptation (PA)
Number of subjects: 80
Study 39173550 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Muscle Vibration (NMV)
Number of subjects: 80
Study 39173550 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Adaptation + Neck Muscle Vibration (PA+NMV)
Number of subjects: 80
Study 39173550 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 39173560 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports (SR)
Number of subjects: 107
Study 39173560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill counts (PC)
Number of subjects: 107
Study 39173560 — intervention group
Group type: COMPARATOR
Intervention: DBS tenofovir concentrations
Number of subjects: 107
Study 39173560 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence (≥90%)
Number of subjects: 107
Study 39173604 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD stage 5 on dialysis
Number of subjects: 105
Study 39173604 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 105
Study 39173604 — intervention group
Group type: COMPARATOR
Intervention: CKD stage 1 and 2
Number of subjects: 105
Study 39173603 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based genetic education (WGE)
Number of subjects: 63
Study 39173603 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 63
Study 39173703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25(OH)D levels in females
Number of subjects: 2370
Study 39173703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25(OH)D levels in females with normal BMI
Number of subjects: 2370
Study 39173703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25(OH)D levels in males with normal BMI
Number of subjects: 2370
Study 39173703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufficient preconception 25(OH)D levels in females with obesity
Number of subjects: 2370
Study 39173703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both partners with sufficient preconception 25(OH)D levels
Number of subjects: 2370
Study 39173703 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception vitamin D status and bioavailability
Number of subjects: 2370
Study 39173703 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy loss
Number of subjects: 2370
Study 39173703 — intervention group
Group type: COMPARATOR
Intervention: Semen quality
Number of subjects: 2370
Study 39173781 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fiducial marker placement using a preloaded 22-gauge EchoTip Ultra Fiducial Needle
Number of subjects: 33
Study 39173781 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fiducial marker placement
Number of subjects: 33
Study 39173973 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Healthy Eating Index for habitual diet
Number of subjects: 359
Study 39173973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal SCFA abundance
Number of subjects: 359
Study 39173973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and microbiome features
Number of subjects: 359
Study 39173973 — intervention group
Group type: EXPERIMENTAL
Intervention: Potatoes
Number of subjects: 359
Study 39173973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine biosynthesis pathway
Number of subjects: 359
Study 39173973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine
Number of subjects: 359
Study 39174002 — intervention group
Group type: EXPERIMENTAL
Intervention: Early point-of-care ultrasound (POCUS) cardiac standstill
Number of subjects: 293
Study 39174002 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal CO2 (ETCO2) value ≤37 mmHg
Number of subjects: 293
Study 39174056 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-PCC (1500 or 2000 international units)
Number of subjects: 410
Study 39174056 — intervention group
Group type: COMPARATOR
Intervention: FP (3 or 4 units depending on body weight)
Number of subjects: 410
Study 39174056 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F-PCC and FP
Number of subjects: 410
Study 39174068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART
Number of subjects: 0
Study 39174285 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care treatment for LTBI
Number of subjects: 362
Study 39174285 — intervention group
Group type: COMPARATOR
Intervention: Secondary care treatment for LTBI
Number of subjects: 362
Study 39174297 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral pathway and interactions with primary care physicians (PCPs)
Number of subjects: 19
Study 39174297 — intervention group
Group type: EXPERIMENTAL
Intervention: Journey undertaken by families from initially trivialising symptoms to a growing sense of urgency
Number of subjects: 19
Study 39174297 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception gap between families' growing disquiet and first medical interventions
Number of subjects: 19
Study 39174297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of guidance from physicians prompting parents to initiate action
Number of subjects: 19
Study 39174297 — intervention group
Group type: EXPERIMENTAL
Intervention: Various elements of the care pathway influencing diagnosis experience
Number of subjects: 19
Study 39174297 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial consequences of delayed diagnosis in JIA
Number of subjects: 19
Study 39174297 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of views and experiences in training programmes and guidelines for PCPs
Number of subjects: 19
Study 39174297 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of online supports integrating medical knowledge and family testimonials
Number of subjects: 19
Study 39174449 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) plus progressive muscle relaxation (PMR) intervention
Number of subjects: 20
Study 39174542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT), and granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 49
Study 39174542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab, SBRT, and GM-CSF
Number of subjects: 49
Study 39174547 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib-tamoxifen
Number of subjects: 184
Study 39174547 — intervention group
Group type: COMPARATOR
Intervention: Placebo-tamoxifen
Number of subjects: 184
Study 39174857 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release form containing 1.9 mg melatonin, 10 mg zinc, and 200 mg lemon balm extract
Number of subjects: 12
Study 39174857 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release form
Number of subjects: 12
Study 39174958 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (50 mJ, 1.5 W/30 Hz, 50% air, 40% water) - Protocol 1 (4 cycles at 2.5 min)
Number of subjects: 3
Study 39174958 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (50 mJ, 1.5 W/30 Hz, 50% air, 40% water) - Protocol 2 (5 cycles at 5 min)
Number of subjects: 3
Study 39174958 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 native implants)
Number of subjects: 3
Study 39175062 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial repellents (SRs) distributed through a reference channel (study personnel distribution)
Number of subjects: 3
Study 39175062 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial repellents (SRs) distributed through a voucher channel
Number of subjects: 3
Study 39175062 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial repellents (SRs) distributed through the Village Health Team channel
Number of subjects: 3
Study 39175082 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDACTIVA intervention (8 sessions over 14 weeks)
Number of subjects: 64
Study 39175082 — intervention group
Group type: COMPARATOR
Intervention: Standard care (2 psychoeducation sessions)
Number of subjects: 64
Study 39175217 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1291583
Number of subjects: 0
Study 39175217 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1291583 with itraconazole
Number of subjects: 0
Study 39175342 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-2-group (warfarin started on day 2 after CS)
Number of subjects: 114
Study 39175342 — intervention group
Group type: COMPARATOR
Intervention: Day-5-group (warfarin started on day 5 after CS)
Number of subjects: 114
Study 39175480 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOPX (CHOP plus targeted agents)
Number of subjects: 96
Study 39175480 — intervention group
Group type: COMPARATOR
Intervention: CHOP (control group)
Number of subjects: 96
Study 39175547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium (6.5 mg/kg initial bolus, 1.6 mg/kg supplemental as needed)
Number of subjects: 256
Study 39175547 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1.5 mg/kg initial bolus, 0.5 mg/kg supplemental as needed)
Number of subjects: 256
Study 39175547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium
Number of subjects: 256
Study 39175547 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 256
Study 39175624 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 24 weeks
Number of subjects: 25
Study 39175624 — intervention group
Group type: COMPARATOR
Intervention: Healthy Aging Education (HE) control intervention
Number of subjects: 25
Study 39175759 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 123
Study 39175759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123